JPRN-UMIN000012883已完成1 期
Multicenter Phase 1b/2 Trial of TAS-102 with Bevacizumab in Patients with Metastatic Colorectal Cancer (mCRC) who had the progression or intolerant to standard therapies. - C-TASK FORCE
ational Cancer Center Exploratory Oncology Research &Clinical Trial Center0 个研究点目标入组 25 人开始时间: 2014年2月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Serious coexisting illness as follows. a. Active double cancer(s) b. CNS metastasis c. Uncontrollable infectious disease d. Uncontrollable pleural effusion, ascites, or cardiac effusion e. Ileus, interstitial pneumonia,renal failure, hepatic failure or cerebrovascular disorder f. Uncontrolled diabetic g. Uncontrolled hypertension h. Cardiac infarction, serious angina or New York Heart Association Class III or IV within 12 months prior to the registration i Gastrointestinal bleeding j Positive HBs antigen, HCV antibody or HIV antibody k. Need immunosuppressive therapy l. Uncontrolled mental disease or the psychotic manifestation 2)Receive the treatment as follows. a.Major surgery therapy within 4 weeks prior to enrollment. b.Chemotherapy within 3 weeks prior to enrollment. c. Wide field radiotherapy 4 weeks prior to enrollment or local radiotherapy 2 weeks prior to enrollment. d.Other investigational drugs within 4 weeks prior to enrollment. 3)Prior treatment with TAS-102 4)Unrecovered AEs related to prior treatment are Grade >= 2 according to CTCAE. 5)Blood transfusion or G-CSF within 14 days prior to enrollment. 6)Serious renal failure or proteinuria >= 2+ within 7days prior to enrollment. 7)Thromboembolic event or serious Pulmonary complaints within 6 months 8)Uncomplete cure wound or traumatic fracture 9)Tendency to hemorrhages or taking antithrombotic medication 10) Women during pregnancy or lactation , 11) Patient is judged by the investigator to be inappropriate for study participation for any reason.
研究者
相似试验
已完成
1 期
A phase I/II trial of TAS-102 in combination with irinotecan in Japanese patients with advanced gastric cancer refractory to standard chemotherapiesadvanced gastric cancer refractory to standard chemotherapiesJPRN-UMIN000031346St. Marianna University School of Medicine11
已完成
2 期
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies(WJOG8916G)Metastatic RAS wild type colorectal cancer which has become refractory or there was intolerance to chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin) and bevacizumab, and refractory to anti-epidermal growth factor receptor(EGFR) antibodiesJPRN-UMIN000027210West Japan Oncology Group55
已完成
2 期
A phase II trial of TAS-102 in combination with cetuximab for patients with RAS wild-type metastatic colorectal cancer refractory to previous anti-EGFR antibodies, accompanying research(WJOG8916GTR)Metastatic RAS wild type colorectal cancer which has become refractory or there was intolerance to chemotherapies (fluoropyrimidine, irinotecan, oxaliplatin) and bevacizumab, and refractory to anti- epidermal growth factor receptor(EGFR) antibodiesJPRN-UMIN000027211West Japan Oncology Group55
招募中
2 期
Phase 2 trial of TAS-102 plus bevacizumab in patients with advanced/recurrent colorectal cancer who had previously received on oxaliplatin, irinotecan and fluoropyrimidineColorectal CancerJPRN-UMIN000026043Tokyo Medical University Department of Gastrointestinal and Pediatric Surgery28
已完成
2 期
A phase II study of TAS-102 plus Bevacizumab therapy for advanced/recurrent colorectal cancer with difficulty on intensive chemotherapyColorectal CancerJPRN-UMIN000022705Osaka medical Center for Cancer and Cardiovascular Diseases20